13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
20 檔
46.9%
At the close of Q3 2025, BML Capital Management, LLC disclosed equity holdings valued at approximately $175.7M, spread across 20 reported holdings.
In Q3 2025, BML Capital Management, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 14 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including ACRS, AVIR, AVU0) accounted for 46.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
CONNECT BIOPHARMA HLDGS LTD
市值: $1.9M
Top Position Liquidated / Trimmed
ANTX
前期市值: $7.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 24.79% | +1.74% | — | |
| 2 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 19.85% | -5.98% | -1.79% | |
| 3 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 12.68% | — | — | |
| 4 | TIL | Instil Bio Inc | Stock-Other | 10.56% | -0.59% | +20.70% | |
| 5 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 7.66% | -4.54% | +2.72% | |
| 6 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 6.78% | -0.18% | +5.84% | |
| 7 | ALMS | Alumis Inc | Stock-Other | 4.42% | — | — | |
| 8 | ✓ | Lava Therapeutics NV | Stock-Other | 2.81% | — | — | |
| 9 | 2KZ0 | Kezar Life Sciences Inc | Stock-Other | 2.57% | -3.43% | EXIT | |
| 10 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 1.75% | +0.09% | — | |
| 11 | IMA | Imagenebio Inc | Stock-Other | 1.36% | +0.03% | — | |
| 12 | LONA | Leonabio Inc | Stock-Other | 1.22% | — | — | |
| 13 | ASTC | Astrotech CORP | Stock-Other | 0.99% | — | — | |
| 14 | TGT | Target CORP | Stock-Consumer Disc | 0.82% | -0.13% | — | |
| 15 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 16 | WMT | Walmart Inc | Stock-Consumer Staples | 0.47% | -0.19% | — | |
| 17 | ARVN | Arvinas Inc | Stock-Other | 0.39% | — | — | |
| 18 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.26% | — | -47.65% | |
| 19 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.11% | — | — | |
| 20 | ✓ | Third Harmonic Bio Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics Inc | +7.1% | — | Unchanged |
| 2 | TIL | Instil Bio Inc | +4.7% | +20.70% | Add |
| 3 | ALMS | Alumis Inc | +4.2% | — | Add |
| 4 | PMVP | Pmv Pharmaceuticals Inc | +3.5% | +5.84% | Add |
| 5 | AVU0 | Adverum Biotechnologies Inc | +3% | — | Add |
| 6 | ORMP | Oramed Pharmaceuticals Inc | +2.4% | +2.72% | Add |
| 7 | AVIR | Atea Pharmaceuticals Inc | +1.4% | -1.79% | Trim |
| 8 | 2KZ0 | Kezar Life Sciences Inc | +1% | +13.48% | Add |
| 9 | ✓ | Lava Therapeutics NV | +0.8% | — | Add |
| 10 | VTGN | Vistagen Therapeutics Inc | +0.2% | — | Unchanged |
| 11 | LSTA | Lisata Therapeutics Inc | -0.2% | -47.65% | Trim |
| 12 | ASTC | Astrotech CORP | -0.2% | — | Unchanged |
| 13 | ✓ | Third Harmonic Bio Inc | -10.7% | — | Unchanged |
| 14 | ANTX | An2 Therapeutics Inc | — | EXIT | Sold out |
| 15 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 16 | ✓ | Ikena Oncology Inc | — | EXIT | Sold out |
| 17 | WHWK | Whitehawk Therapeutics Inc | — | EXIT | Sold out |
| 18 | ✓ | Connect Biopharma Hldgs LTD | — | NEW | New buy |
| 19 | ✓ | Elevation Oncology Inc | — | EXIT | Sold out |
| 20 | IMA | Imagenebio Inc | — | NEW | New buy |
| 21 | LONA | Leonabio Inc | — | NEW | New buy |
| 22 | CNTB | Connect Biopharma Holdings Limited | — | EXIT | Sold out |
| 23 | SG7 | Sage Therapeutics Inc | — | EXIT | Sold out |
| 24 | ✓ | Athira Pharma Inc | — | EXIT | Sold out |
| 25 | MIST | Milestone Pharmaceuticals In | — | EXIT | Sold out |
| 26 | TGT | Target CORP | — | NEW | New buy |
| 27 | WMT | Walmart Inc | — | NEW | New buy |
| 28 | ✓ | Turnstone Biologics CORP | — | EXIT | Sold out |
| 29 | ARVN | Arvinas Inc | — | NEW | New buy |
| 30 | NXTCEUR | Nextcure Inc | — | EXIT | Sold out |
| 31 | ✓ | Mural Oncology Pub LTD Co | — | NEW | New buy |
| 32 | ✓ | Verrica Pharmaceuticals Inc | — | EXIT | Sold out |
| 33 | ✓ | Hillevax Inc | — | EXIT | Sold out |
| 34 | 698 | Achilles Therapeutics Pl-adr | — | EXIT | Sold out |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 20 disclosed positions in Q3 2025.
During Q3 2025, BML Capital Management, LLC's top holdings by market value included ACRS (24.8%)、AVIR (19.9%)、AVU0 (12.7%). The largest single position, ACRS, represented 24.8% of total portfolio value.
In Q3 2025, BML Capital Management, LLC made 30 total portfolio adjustments, initiating 7 new buys, adding to 7 positions, trimming 2 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.